✔ 100% Authentic Product
👁️ Currently Viewing 499
Dasacent 100mg Tablet 1 Strip
Dasacent is a medication primarily used for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in both adult and pediatric patients.
- Adults:
- Newly diagnosed Ph+ CML in chronic phase.
- Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
- Ph+ ALL with resistance or intolerance to prior therapy.
- Pediatric patients (1 year and older):
- Ph+ CML in chronic phase.
- Newly diagnosed Ph+ ALL in combination with chemotherapy.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cash on Delivery - All over Bangladesh
Regular Delivery - 8-12 Hours, Dhaka City*- Regular Delivery - 24-48 Hours, All Over Bangladesh*
✅ Description:
- Mechanism of Action: Dasatinib inhibits several kinases including BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ. This inhibition helps overcome Imatinib resistance and targets various signaling pathways involved in leukemia progression.
- Absorption: Peak plasma concentrations are reached between 0.5 to 6 hours after oral administration.
- Metabolism: Primarily metabolized by CYP3A4, with minor contributions from other enzymes like FMO-3 and UGT.
- Excretion: Mostly excreted in the feces, with only 4% excreted in urine.
Relevant Products / প্রাসঙ্গিক পণ্য
✔️ Side Effects
- Common side effects include myelosuppression, bleeding events, fluid retention, cardiovascular issues, pulmonary arterial hypertension, QT prolongation, and severe dermatologic reactions like Stevens-Johnson syndrome.
✔️ Dosage & Administration
- Adult Dosage:
- Chronic Phase CML: 100 mg orally once daily.
- Accelerated phase, blast phase CML, or Ph+ ALL: 140 mg orally once daily.
- Pediatric Dosage:
- Based on weight (starting from 40 mg/day for children weighing 10-20 kg, to 100 mg/day for those weighing 45 kg or more).
✔️ Interactions
- CYP3A4 Inhibitors: Can increase Dasacent concentrations and may raise the risk of toxicity.
- CYP3A4 Inducers: Can decrease Dasacent concentrations and reduce efficacy.
- Gastric Acid Reducing Agents: May reduce Dasacent's effectiveness; avoid use with H2 antagonists or proton pump inhibitors.
✔️ Pregnancy & Lactation
- Pregnancy: Dasatinib can cause fetal harm and should not be used during pregnancy unless necessary.
- Breastfeeding: Not recommended due to excretion in breast milk.
✔️ Precautions
- Myelosuppression: Regular blood count monitoring is required, especially in advanced disease stages.
- Bleeding: Monitor for hemorrhage risks, especially if on anticoagulants.
- Pulmonary Arterial Hypertension (PAH): Patients should be monitored for PAH, which may require discontinuation of treatment.
- QT Prolongation: Risk in patients with electrolyte imbalances or on other QT-prolonging drugs.
✔️ Storage
- Store below 30°C in a dry place, away from light, and out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.
